BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Seiwert, Tanguy Y.; Clément, Paul M.; Cupissol, Didier; Campo, J. Del; Mont-Serrat, H. de; Thurm, Holger; Blackman, Alice; Cohen, Ezra E.W.

doi:10.1200/jco.2010.28.15_suppl.5501

Cited by 27 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of oral tyrosine kinase inhibitors (TKI) in HNSCC has been largely disappointing, with recent phase III trials demonstrating no benefit for gefitinib over methotrexate or in combination with docetaxel in patients with R/M HNSCC (Table 4). 80,81 More recent studies with irreversible EGFR TKI such as afatanib (BIBW2992) have yielded more promising results but the results of phase III studies are awaited 82 …”

Section: Targeted Therapiesmentioning

confidence: 99%

The emerging era of personalized therapy in squamous cell carcinoma of the head and neck

Pryor

Solomon

Porceddu

2011

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Over the past three decades there has been a move toward organ preservation protocols in the management of locally advanced mucosal head and neck squamous cell carcinomas (LAHNSCC) with combinations of radiotherapy (RT), chemotherapy and, more recently, biological agents. Current standard chemoradiation strategies have reached the upper limits of toxicity. In addition, the traditional one size fits all approach of grouping patients according to traditional clinicopathological features fails to take into account the vast underlying biological heterogeneity of tumors and their host. A number of recent advances such as highly conformal RT, molecular profiling and targeted agents, and improvements in treatment response assessment have set the scene for a fundamental paradigm shift toward greater tailoring of therapy with the aim of improving outcomes and reducing the burden of survivorship. This review focuses on the recognition of the prognostic value of tumor human papillomavirus (HPV) status, the incorporation of biologically targeted therapies and the evolving role of molecular imaging in predicting tumor response and prognosis in the curative management of LAHNSCC.

show abstract

Section: Targeted Therapiesmentioning

confidence: 99%

The emerging era of personalized therapy in squamous cell carcinoma of the head and neck

Pryor

Solomon

Porceddu

2011

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…10 Newer generation of EGFR TKIs are being evaluated, including for example, the irreversible dual EGFR/HER2 inhibitor afatinib – preliminary results of a randomized phase II study demonstrated comparable efficacy with cetuximab in terms of response rates in previously treated patients with incurable HNSCC. 11 …”

Section: Egfr-targeted Agents For Treatment Of Hnsccmentioning

confidence: 99%

Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention

Mak

William

2014

Oral Oncology

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) has been implicated in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. It is currently the only molecular target in head and neck cancers for which there are pharmacologic therapeutic interventions approved by regulatory agencies worldwide to treat advanced disease. Oral pre-malignant lesions have increased EGFR protein expression and increased egfr gene copy number compared to normal mucosa. Oral pre-malignant lesions with overexpression of EGFR or egfr gene copy number gain are at higher risk for malignant transformation. Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates this approach as an effective way to reduce the incidence of oral cancer, and supports investigation of this strategy in the clinic. Clinical trials with EGFR targeted agents, including cetuximab, erlotinib, and vandetanib, are currently under way, some with promising preliminary results. If ultimately shown to reduce the risk of oral cancer, chemoprevention with EGFR inhibitors may significantly reduce morbidity and possibly mortality from HNSCC.

show abstract

“…A number of palliative treatment protocols, predominantly involving chemotherapy or molecular targeting agents, have been tested in clinical trials [1,2,4,7,10,11,13,[16][17][18]. Many of these experimental treatment strategies failed to produce results for their incorporation into clinical standard treatment guidelines.…”

Section: Introductionmentioning

confidence: 99%

Palliative treatment standards for head and neck squamous cell carcinoma

Laban

Kimmeyer

Knecht

et al. 2016

HNO

View full text Add to dashboard Cite

Palliative systemic therapy seems to be well standardized for first-line treatment, whereas there is little standardization in second- and third-line treatments. A large variation was found regarding the estimate of the applicability of the institutional standard. Reasons for this could be the physicians' individual experience as well as the varying assessment regarding the toxicity of palliative systemic therapy.

show abstract

BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Cited by 27 publications

References 0 publications

The emerging era of personalized therapy in squamous cell carcinoma of the head and neck

The emerging era of personalized therapy in squamous cell carcinoma of the head and neck

Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention

Palliative treatment standards for head and neck squamous cell carcinoma

Contact Info

Product

Resources

About